Dr. James Michael Melotek, MD

Dr. Melotek practices at Saint Lucie Radiation Oncology in Port Saint Lucie, Florida.

Dr. Melotek's NPI, 1255696696, was assigned on July 11, 2012. Dr. Melotek graduated from University Of Florida College Of Medicine in 2012. Dr. Melotek holds Florida license ME133523.

Dr. Melotek's primary practice is Saint Lucie Radiation Oncology, at 8980 S Us-1, Port Saint Lucie, FL 34952 in Saint Lucie County. The practice phone is (772) 281-3060.

Dr. Melotek's primary practice is Saint Lucie Radiation Oncology in Port Saint Lucie, Florida. Dr. Melotek is also affiliated with Cleveland Clinic Martin North Hospital. The medical group on file is Saint Lucie Radiation Oncology. Dmand AI also links Dr. Melotek to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Melotek practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Melotek's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Melotek is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Melotek's licenses on file in 2 states: Florida and Illinois.

Dmand AI lists anal cancer radiation, bladder cancer radiation, bone cancer radiation, brain cancer radiation, brain tumor radiation, breast cancer radiation, cancer radiation-upper GI and colorectal cancer radiation among the conditions Dr. Melotek treats.

CMS data shows 7,569 Medicare services from Dr. Melotek across 22 procedure codes in 2024, for 303 Medicare patients. Medicare paid $1,495,229 for them. Every service was in an office.

CMS counts 303 Medicare patients who saw Dr. Melotek in 2024. The largest group is 65 to 74, with 127 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Melotek's median patient age at 73, with 30% women.

In 2024, Dr. Melotek wrote 667 Medicare Part D claims for 239 patients. 95% of them were for generic drugs. CMS names the drug for 496 of them, across 19 drugs with 11 or more claims each, at $7,102 in total drug cost. In 2023, CMS named 350 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Melotek for performance year 2024, reported individually. Dr. Melotek accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 14 papers to Dr. Melotek, published from 2011 to 2021. 2016 was the busiest year, with 3. The most frequent topics are Chemoradiotherapy, Antineoplastic Combined Chemotherapy Protocols and Carcinoma, Squamous Cell. Dr. Melotek has published most often in Ann Oncol. Dr. Melotek's most frequent co-authors are Daniel J. Haraf, Nishant Agrawal and Steven J. Chmura.

CMS Open Payments shows 42 general payments to Dr. Melotek from 24 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 76% of the total. RefleXion Medical, Inc. paid the most, $995.

Dmand AI lists 1 award for Dr. Melotek, most recently AOA Inductee 2011 in 2011.

Dr. Melotek graduated from University Of Florida College Of Medicine in 2012. Dr. Melotek is a member of AOA.

Dr. Melotek is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.